CN106573071A - 用于治疗癌症和炎症性疾病的偶联物和前药 - Google Patents

用于治疗癌症和炎症性疾病的偶联物和前药 Download PDF

Info

Publication number
CN106573071A
CN106573071A CN201580018638.0A CN201580018638A CN106573071A CN 106573071 A CN106573071 A CN 106573071A CN 201580018638 A CN201580018638 A CN 201580018638A CN 106573071 A CN106573071 A CN 106573071A
Authority
CN
China
Prior art keywords
group
conjugate
prodrug
functional group
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580018638.0A
Other languages
English (en)
Chinese (zh)
Inventor
塞巴斯蒂安·帕波
伊莎贝尔·奥帕林斯基
布丽奇特·勒努
蒂博·莱吉甘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Poitiers filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CN202210334259.4A priority Critical patent/CN114917358A/zh
Publication of CN106573071A publication Critical patent/CN106573071A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201580018638.0A 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药 Pending CN106573071A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210334259.4A CN114917358A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1450956 2014-02-07
FR1450956A FR3017298B1 (fr) 2014-02-07 2014-02-07 Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
PCT/IB2015/050914 WO2015118497A1 (fr) 2014-02-07 2015-02-06 Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210334259.4A Division CN114917358A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药

Publications (1)

Publication Number Publication Date
CN106573071A true CN106573071A (zh) 2017-04-19

Family

ID=50829100

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580018638.0A Pending CN106573071A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药
CN202210334259.4A Pending CN114917358A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210334259.4A Pending CN114917358A (zh) 2014-02-07 2015-02-06 用于治疗癌症和炎症性疾病的偶联物和前药

Country Status (9)

Country Link
US (1) US10293021B2 (enExample)
EP (2) EP3139963B1 (enExample)
JP (1) JP6721512B2 (enExample)
CN (2) CN106573071A (enExample)
CA (1) CA2938501C (enExample)
DK (1) DK3139963T3 (enExample)
ES (1) ES2843798T3 (enExample)
FR (1) FR3017298B1 (enExample)
WO (1) WO2015118497A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004556A (zh) * 2018-04-03 2020-11-27 辛迪维亚公司 细胞毒性药物的结合物和所述结合物的前体药物形式
CN114173877A (zh) * 2019-05-06 2022-03-11 施科友智能化学疗法公司 用于治疗癌症的新的治疗载体和前药
CN116077674A (zh) * 2022-12-26 2023-05-09 北京大学 生物分子-聚氮氧化物偶联物及其制备方法与应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722593B2 (en) 2015-10-02 2020-07-28 Sirenas Llc Anti-cancer compounds and conjugates thereof
CN108779146B (zh) * 2016-03-29 2022-03-18 东丽株式会社 肽衍生物及其用途
US11666657B2 (en) 2017-05-16 2023-06-06 Universite De Strasbourg Protein-drug conjugates and their use in the treatment of cancers
AU2018375787B2 (en) * 2017-11-30 2023-02-23 Ladrx Corporation Albumin-binding prodrugs of auristatin E derivatives
FR3126982B1 (fr) * 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PT3248613T (pt) * 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
FR2960153B1 (fr) * 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ISABELLE TRANOY-OPALINSKI ET AL.: ""β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
KAI TEMMING ET AL.: ""Evaluation of RGD-Targeted Albumin Carriers for Specific Delivery of Auristatin E to Tumor Blood Vessels"", 《BIOCONJUGATE CHEMISTRY》 *
THIBAUT LEGIGAN ET AL.: ""The First Generation of b-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy"", 《ANGEWANDTE COMMUNICATIONS》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004556A (zh) * 2018-04-03 2020-11-27 辛迪维亚公司 细胞毒性药物的结合物和所述结合物的前体药物形式
CN114173877A (zh) * 2019-05-06 2022-03-11 施科友智能化学疗法公司 用于治疗癌症的新的治疗载体和前药
CN114173877B (zh) * 2019-05-06 2024-12-10 施科友智能化学疗法公司 用于治疗癌症的新的治疗载体和前药
CN116077674A (zh) * 2022-12-26 2023-05-09 北京大学 生物分子-聚氮氧化物偶联物及其制备方法与应用

Also Published As

Publication number Publication date
ES2843798T3 (es) 2021-07-20
CN114917358A (zh) 2022-08-19
EP3766510A1 (fr) 2021-01-20
US10293021B2 (en) 2019-05-21
CA2938501A1 (fr) 2015-08-13
FR3017298A1 (fr) 2015-08-14
JP2017506628A (ja) 2017-03-09
DK3139963T3 (da) 2020-10-26
EP3139963B1 (fr) 2020-10-07
JP6721512B2 (ja) 2020-07-15
CA2938501C (fr) 2022-04-05
US20170095525A1 (en) 2017-04-06
FR3017298B1 (fr) 2016-03-04
WO2015118497A1 (fr) 2015-08-13
EP3139963A1 (fr) 2017-03-15

Similar Documents

Publication Publication Date Title
CN106573071A (zh) 用于治疗癌症和炎症性疾病的偶联物和前药
TWI851531B (zh) 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
CN114732916B (zh) 含叔胺药物物质的靶向递送
EP2740493A1 (en) Conjugates of the B-subunit of Shiga toxin for anticancer therapies
US12454527B2 (en) Conjugate monomethyl auristatin E to obtain a composition for treatment of prostate cancer
HK1236815A1 (en) Conjugates and prodrugs for treating of cancer and inflammatory diseases
CN114173877B (zh) 用于治疗癌症的新的治疗载体和前药
US20240424118A1 (en) Vectors targeting beta-d-n-acetylglucosaminidase
HK40079820B (zh) 含叔胺药物物质的靶向递送
HK40079820A (en) Targeted delivery of tertiary amine-containing drug substances
JP2025507676A (ja) ヒドロキシアパタイト標的造影および療法のための、コンジュゲート、組成物および方法
BR112017003975B1 (pt) Composição de conjugado de ligante e fármaco, e, composto ligador de fármaco

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1236815

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170419

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1236815

Country of ref document: HK